Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: A double-blind trial

Piero Barbanti, Luisa Fofi, Valentina Dall'Armi, Cinzia Aurilia, Gabriella Egeo, Nicola Vanacore, Stefano Bonassi

Research output: Contribution to journalArticle


The objective and background is to confirm in a double-blind, placebo-controlled study the high triptan response rates we had previously reported in an open study in migraine patients with unilateral cranial autonomic symptoms. In this randomized, double-blind, placebocontrolled study 80 migraineurs with unilateral cranial autonomic symptoms were assigned to receive rizatriptan 10 mg wafer or placebo (ratio 1:1) and treated for a single moderate or severe migraine attack. The primary endpoints were pain freedom at 2 h and total migraine freedom at 2 h. Secondary endpoints included pain relief, no associated symptoms and sustained pain freedom or relief. Significantly more patients reported pain freedom at 2 h after taking rizatriptan (54 %) than after placebo (8 %) (therapeutic gain 46 % [28 %; 64 %]; P

Original languageEnglish
Pages (from-to)407-414
Number of pages8
JournalJournal of Headache and Pain
Issue number5
Publication statusPublished - Jul 2012



  • Cranial autonomic symptoms
  • Migraine
  • Rizatriptan
  • Treatment
  • Trigemino-autonomic reflex

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this